A comprehensive description of transcatheter heart valve (THV) failure has not been performed. We undertook a systematic review to investigate the aetiology, diagnosis, management, and outcomes of THV failure.
Introduction
Transcatheter aortic valve implantation (TAVI) is a rapidly proliferating technology with the potential to become the dominant treatment strategy for aortic valve stenosis in patients at excessive-or high-operative risk. 1 Improving procedural safety and promising medium-term clinical efficacy have encouraged the application of transcatheter heart valve (THV) technology to lower risk cohorts. 2 -5 In this context, understanding the modes of THV failure and demonstrating valve durability and long-term clinical efficacy are of vital importance. It is estimated that 200 000 patients worldwide undergo surgical aortic valve replacement (SAVR) annualy. 6 Bioprosthetic surgical heart valves are the most frequently implanted prostheses, especially
Definitions
Prosthetic valve endocarditis (PVE) was defined according to the updated Valve Academic Research Consortium (VARC) criteria, 11 and was classified as possible or definite according to the modified Duke criteria. 12 Transcatheter heart valve embolization represents an SVF occurring when the forces acting on the valve frame overcome the strength of the valve's attachment to the native aortic annulus. 13 Late THV embolization may be defined as valve migration after a successful TAVI procedure where further THV-related intervention is not envisaged. Transcatheter heart valve SVF was defined according to the updated VARC criteria: 11 valve-related dysfunction demonstrated by a mean aortic valve gradient ≥20 mmHg, an effective orifice area of ≤0.9 (BSA ≥ 1.6 cm ) and/or a Doppler velocity index ≤ 0.35, and/or moderate or severe prosthetic valve regurgitation (regurgitant volume . 30 mL, regurgitant fraction . 30%, effective regurgitant orifice area .0.10 cm 2 ), or the requirement for a repeat procedure (TAVI or SAVR). We defined THV compression as distortion of the valve on noninvasive imaging or at autopsy, potentially impairing valve function or necessitating further intervention. Compression had to be temporally related to chest wall trauma or CPR. Transcatheter heart valve thrombosis was defined according to the updated VARC criteria: 11 noninfective thrombus attached to the valve leaflets or frame that impedes blood flow, valve function, or is sufficiently large to require treatment.
Statistics
Categorical variables were reported as number (%), and continuous variables were reported as mean and SD or median and interquartile range, according to distribution. Analyses were performed with SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
The initial literature search identified a total of 2400 publications ( Figure 1) . Removal of non-pertinent studies and duplicates by title screening yielded 82 potentially relevant articles that were examined in detail. Finally, 70 publications fulfilled our study inclusion and exclusion criteria, and reported 87 individual cases of THV failure ( Figure 2 ). All studies discussed single case reports or small series and the baseline characteristics of these patients were typical of Transcatheter heart valve failure the elderly high-risk cohorts undergoing TAVI in previously reported large registries. 14 -16 Transcatheter heart valve-prosthetic valve endocarditis
A total of 26 publications, describing 34 cases of THV PVE were identified ( Table 1) . 17 -42 Among these patients, the median age was 83 (77, 85) years and most (n ¼ 20, 59%) presented risk factors predisposing to PVE: diabetes mellitus (n ¼ 10), chronic kidney disease (n ¼ 12), immunosuppression (n ¼ 2), and recurrent infections (n ¼ 4). Several factors may have contributed to the development of PVE, including suboptimal THV positioning causing injury to the anterior mitral valve leaflet, 17, 18, 40 failure to administer antibiotic prophylaxis prior to TAVI (n ¼ 1) or dental (n ¼ 3) procedures. There were 29 (85%) cases of definite and 5 (15%) cases of possible PVE according to the modified Duke criteria. The median time to IE diagnosis was 6 (3, 12) months, with early (,60 days), intermediate (60 days to 1 year), and late (.1 year) IE classified in 6 (18%), 21 (62%), and 7 (20%) patients, respectively. Cases of PVE were noted with both the Edwards SAPIEN (Edwards Lifesciences Inc., Irvine, CA, USA) (n ¼ 20, 59%) and Medtronic CoreValve (Medtronic Inc., Minneapolis, MN, USA) (n ¼ 14, 41%) prostheses. Similar numbers of PVE cases were observed with transfemoral and transapical vascular access (both n ¼ 12). A total of 27 patients had positive blood cultures with a microbiological profile typical to that previously documented in surgical bioprosthetic PVE: Enterococcus species (n ¼ 10), coagulase-negative Staphylococci (n ¼ 5), Staphylococcus aureus (n ¼ 3), Streptococcus species (n ¼ 5), and Histoplasma capsulatum (n ¼ 1). Three patients were culture negative and blood cultures were not performed in two cases. Echocardiography demonstrated mobile vegetations or abscess formation in 18 patients, progressive THV stenosis/regurgitation in 3 cases, and was reportedly normal in 3 patients. Abscess formation was described in 8 cases: aortic root (n ¼ 3), aortic sinus (n ¼ 2), annular (n ¼ 1), and paravalvular (n ¼ 2). Interestingly, 'bridging' endocarditis between the aortic THV and a satellite infection on the mitral valve was noted in 8 (24%) patients.
Treatment options for PVE include targeted antibiotic therapy or surgical intervention. In the current series, 20 (59%) patients were treated medically (7 died in-hospital, 13 discharged home [1 death at 3 months with sepsis, 6 alive at 1 year, 6 further outcome unknown), and 14 (41%) underwent surgical intervention (3 died, 9 discharged home, 2 outcome unknown). Surgical intervention consisted of THV retrieval and SAVR (n ¼ 13), with concomitant aortic root replacement (n ¼ 2), mitral or tricuspid repair/replacement (n ¼ 5).
Discussion: prosthetic valve endocarditis
The incidence of surgical PVE is estimated at 0.3 -1.2% per patientyear. 12 To date, the incidence of early THV PVE has been reported to be between 0.3 and 3.4%. 5, 28, 43 Amongst 180 consecutive TAVI recipients (median follow-up 319 days), Puls et al. observed five cases of PVE, thus yielding an incidence rate of 3.4% at 1-year. 28 Direct comparisons between these rates may be misleading given the complexity of patients undergoing TAVI and heterogeneity in reporting styles. In the PARTNER (Placement of Aortic Transcatheter Valves) trial (Cohort A), PVE occurred at a similar rate in the surgical and transcatheter groups (1.5 and 1.0%, respectively, P ¼ 0.61). 5 The incidence of PVE may also be influenced by patient risk profile and behaviour: diabetes mellitus, oral hygiene, and adherence to antibiotic prophylaxis. 44 Physician behaviour, and in particular adherence to recommendations regarding antibiotic prophylaxis, can also impact on the development of PVE. 45 Accurate quantification of the risk of THV PVE will require further study of large patient populations with extended follow-up. While one can speculate that the less invasive nature of TAVI could be reflected in lower rates of early PVE, the converse is also plausible. The non-sterile environment of many cardiac catheterization laboratories, high-risk profile of TAVI patients, and specific technical issues, including the infrequent requirement to remove, resheath, and reimplant a malpositioned THV could potentially increase the risk of PVE ( Figure 3) . It is therefore of critical importance that every effort is made to minimize the risk of PVE: patient education, especially regarding the importance of post-implantation antibiotic prophylaxis; early treatment of coincident infections; and maintenance of a sterile environment during the index procedure. Interestingly, 24% of PVE cases involved 'satellite' endocarditis of the mitral valve, 17, 18, 20, 35, 36 suggesting that 'bridging-PVE' may occur when a low-lying aortic THV that is in direct contact with the mitral apparatus. 46 Secondary mitral valve involvement has been reported in 10% of native aortic valve endocarditis cases and is associated with a poor prognosis. 47 Confirming the diagnosis of THV PVE can be challenging as elderly TAVI patients may present insidious and atypical symptomatology, and have a co-existing predisposition to infectious pathogens. 12 High rates of empiric antibiotic therapy in the elderly and difficulty in assessing the typical echocardiographic features of PVE can also hinder diagnostic certainty. 48, 49 New valvular regurgitation is also difficult to differentiate from post-procedural paravalvular leaks and prosthetic dehiscence does not occur as radial force rather than sutures anchor the THV in situ. Consequently, the modified Duke criteria may be more difficult to apply in TAVI cohorts. 12 This diagnostic uncertainty is demonstrated by delayed diagnosis observed among several THV PVE cases. 18, 22, 25, 27, 28 Targeted antibiotic therapy remains the first line of treatment for THV PVE. While conventional indications for operative intervention in the setting of PVE may be less applicable to high-risk TAVI cohorts, in this series surgical management of PVE (THV retrieval and SAVR and concomitant aortic root replacement, mitral or tricuspid repair) was associated with encouraging outcomes (75% survived to hospital discharge). Thus, surgery for PVE should not be discounted among TAVI recipients, and Heart Team discussion is encouraged for all such cases.
Late transcatheter heart valve embolization
Late THV embolization represents a new complication previously unreported in the surgical bioprosthetic valve literature. We identified 18 cases of late THV embolization associated with the Edwards SAPIEN (n ¼ 15) and Medtronic CoreValve (n ¼ 3) ( Table 2) .
40,50 -66 The mean age of these patients was 77 + 6 years. 
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Transcatheter heart valve failure On average, late THV embolization occurred 43 + 41 days (range: 4 h to 370 days) after the index procedure. Valve embolization was retrograde into the left ventricular outflow tract (LVOT) in 16 (89%) cases and anterograde into the aorta in 2 (11%).
The initial THV position was described as correct in 4 patients and low in 6 (THV position not described in 8 cases: 6 uneventful procedures, 2 no procedural outcome reported). Suboptimal procedural outcomes resulted in implantation of a 2nd THV (n ¼ 2), elevated transvalvular gradients (n ¼ 4), and/or moderate aortic regurgitation (n ¼ 1: severe transvalvular regurgitation; n ¼ 3: moderate paravalvular regurgitation). The clinical presentation of THV embolization was usually with rapid haemodynamic collapse (n ¼ 2) or acute pulmonary oedema (n ¼ 10). Two patients had late embolization diagnosed as an incidental finding on echocardiography and one developed progressive heart failure. Echocardiographic studies demonstrated severe aortic incompetence in 10 (56%) of cases, LVOT obstruction in 5 (28%), and interaction with the anterior mitral valve leaflet and mitral regurgitation in 4 (22%).
Management of THV embolization included acute haemodynamic stabilization or heart failure management, as required. Subsequent surgical intervention (THV retrieval and SAVR) was performed in 14 of 18 patients (78%), with survival to hospital discharge noted in 62% of cases. One patient deteriorated rapidly following THV embolization, and the Heart Team considered further surgical intervention to be futile. Three patients were treated by implantation of a second THV within the embolized prostheses in the LVOT (TAV-in-TAV): successful implantation of a 29 mm Edwards SAPIEN within a 26 mm Edwards SAPIEN (patient discharged home); implantation of a 29 mm CoreValve within a 31 mm CoreValve (patient died from cerebral anoxia); and successful implantation of a 26 mm Edwards SAPIEN in a 29 mm CoreValve (patient discharged home).
Discussion: late transcatheter heart valve embolization
Several patient and procedural factors may pre-dispose to late THV embolization ( Figure 4 ): (i) undersizing of the THV, 54, 63 (ii) underexpansion of an appropriately sized THV due to aortic root calcification, 51, 60 57, 59 and high transvalvular gradients. 54, 55, 61 In this setting, elevated gradients could potentially be explained by undersizing or incomplete expansion of the THV, 54 low implantation with consequent 'overhang' of the native stenotic leaflets, 61, 63 or by inversion of the THV following rotation within the LVOT. 55 Initial excessively deep implantation of the THV is obviously a risk factor for delayed embolization into the LVOT, and was described in 6 cases in the current series. 56 Left ventricular (89%) rather than aortic (11%) embolization was predictably more common given the fact that the retrograde forces acting on the THV in diastole amount to 10 times the anterograde forces in systole, 13 and that deep THV implantation may have been a precipitating factor. The clinical presentation of late THV embolization was variable, but most patients (80%) developed abrupt left ventricular failure and cardiogenic shock. Urgent operative intervention, to remove the embolized THV and replace the aortic valve, was performed in most cases (78%). Two-thirds of patients that underwent urgent surgery survived to hospital discharge. This observation underscores the importance of the Heart Team and supports operative intervention among selected TAVI recipients. Among the three patients treated with TAV-in-TAV, two survived to hospital discharge. The haemodynamic results of the TAV-in-TAV procedures were not reported.
Structural valve failure
To date, 13 individual reports of THV SVF have been reported: 9 Edwards SAPIEN and 4 CoreValve ( Table 3) . 67 -77 The mean age of these patients was 80 + 7 years and the mean time to SVF was 24 + 26 months (range: several days to 5.5 years). Among the 7 cases detailing acute procedural results, 3 had no aortic regurgitation, 3 mild paravalvular leaks, and 1 mild transvalvular leak. The latter case initially required post-implantation balloon dilatation for moderate paravalvular leak and over subsequent days developed progressive transvalvular aortic regurgitation requiring implantation of a 2nd THV. Excluding this patient, 3 asymptomatic patients were diagnosed with moderate valve dysfunction on echocardiography, and the remaining 7 cases represented with recurrent dyspnoea or congestive heart failure. Echocardiography demonstrated moderate prosthesis stenosis or regurgitation in 5 cases, severe stenosis in 5, and severe regurgitation in 3 cases. Structural valve failure was attributed to severe leaflet calcification (n ¼ 3), cusp rupture (n ¼ 1), THV underexpansion (n ¼ 2), and tissue ingrowth (n ¼ 2) causing restrictive leaflet function. The failure mode was unclear or not described in 6 cases. Three asymptomatic patients with moderate valve dysfunction were managed conservatively, and the remaining patients underwent THV retrieval and SAVR (n ¼ 4) or implantation of a second THV within the previously sited valve (n ¼ 6) (TAV-in-TAV). Among the 4 patients who underwent THV retrieval and SAVR, intraoperative findings were: (Case 1) normal functioning CoreValve with no pannus or paravalvular leak, (Case 2) ingrowth of inflammatory tissue restricting the non-coronary leaflet of an Edwards SAPIEN XT, (Case 3) incomplete expansion of an Edwards SAPIEN valve within a 21 mm Hancock bioprosthesis, and (Case 4) severe calcification of both surfaces of the CoreValve leaflets. Favourable clinical outcomes were reported in all cases, except in one patient that underwent TAV-in-TAV and suffered a peri-procedural stroke.
Discussion: structural valve failure
Bioprosthetic SVF is a chronic degenerative process characterized by calcium phosphate deposition and extracellular matrix deterioration. The aetiology primarily relates to the chronic mechanical stresses on the valve leaflet's regions of maximal flexion, thus compromising structural integrity of leaflet tissue and initiating calcium deposition. 78 Glutaraldehyde fixation, residual leaflet antigenicity, and systemic atherosclerosis may also contribute to the pathogenesis of SVF. 79 -81 With surgical bioprosthetic valves, freedom from re-operation or death at 10 and 15 years are between 70 -90 and 50 -80%, respectively. 82 Freedom from re-operation or death, however, is not synonymous with SVF, which is defined according to echocardiographic or haemodynamic criteria. Thus, surgical SVF may be under-reported in the literature. With respect to TAVI, the relative infancy of this technique prohibits meaningful discussion of the rates of long-term SVF. Nevertheless, the short-to medium-term incidences of THV SVF are low. 14, 75, 83 In a pan-Canadian study of 339 TAVI recipients, RodesCabau et al. 
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Transcatheter heart valve failure up, Toggweiler et al. 75 reported structural valve deterioration in 3.4% of cases: moderate stenosis (n ¼ 1), moderate regurgitation (n ¼ 1), and moderate mixed disease (n ¼ 1). There were no cases of reoperation. Similarly, in the PARTNER trial (Cohort A), no patients in either the surgical or transcatheter groups had SVF at 2 years of follow-up. 4 Although much longer-term follow-up (.10 years) will be required to demonstrate the true incidence of SVF associated with TAVI, this may be difficult to accrue due to the elderly and highrisk nature of TAVI recipients. Among the reported cases of THV SVF, leaflet calcification, tissue ingrowth (pannus), and incomplete THV expansion were the most commonly described failure mechanisms. 69,71 -73,77 There may be, however, specific failure mechanisms unique to THV ( Figure 5 ). In particular, the haemodynamic sheer stress on the THV leaflets may be significantly increased in cases of incomplete THV expansion or in very elliptical annuli. 68, 70, 77, 84, 85 THV thrombosis can also mimic SVF, by presenting with elevated transvalvular gradients, and should be excluded using multimodal imaging. In one case, the authors speculated that post-implantation balloon dilatation may have resulted in tearing of a CoreValve leaflet, inducing severe transvalvular aortic regurgitation. 67 Balloon expansion has been demonstrated to cause microscopic leaflet injury; 86 however, the frequency with which post-implantation is performed suggests that balloon-related trauma is unlikely to represent an important cause of SVF. In surgically implanted bioprosthetic valves, tearing of valve leaflets has been observed in up to 70 -80% of cases implanted for over 10 years, and is often accompanied by calcification. 87 Tearing of the valve leaflet in a horizontal plane running parallel to the sewing ring is unique and is reported in 10 -15% of cases. 87 This type of leaflet tearing, to our knowledge, has not yet been observed in TAVI.
The majority of patients with SVF requiring intervention were treated with TAV-in-TAV (60%), rather than SAVR (40%). Outcomes of both procedures were excellent, with no deaths and only one periprocedural stroke in a patient that underwent transapical TAV-in-TAV. 74 Transcatheter heart valve compression
Compression of a bioprosthetic heart valve is a recently described phenomenon that may be to be unique to balloon-expandable THVs. We identified seven cases of Edwards SAPIEN valve compression that occurred following CPR in the setting of cardiac arrest (Table 4) . 33,40,88 -92 The median time to cardiac arrest was 3 days (range: 12 min to 42 days). Transcatheter heart valve compression was identified on fluoroscopy in one case and at autopsy in all others. Although the resuscitation efforts were ultimately unsuccessful in all patients, it was not possible to implicate THV compression in the demise of these patients that had suffered serious life-threatening complications. No patient received any specific intervention for THV compression.
Discussion: Transcatheter heart valve compression
Prior studies have reported compression of both coronary stents and of the Melody transcatheter pulmonary valve (Medtronic) following CPR. 93, 94 Despite event. 95 Underreporting is likely as almost all cases were diagnosed post-mortem. To date, all cases of THV compression involve balloon-expandable TAVI systems, specifically the Edwards SAPIEN prostheses. Although speculative, balloon-expandable THV may be more susceptible to deformation compared with self-expanding THV, as the stainless steel (SAPIEN) or cobalt-chromium (SAPIEN XT) composition does not have the shape memory properties of Nitinol (CoreValve) ( Figure 6 ). Although normal CoreValve integrity has been reported following prolonged CPR (Personal communication; Nawwar Al-Attar, PCR London Valves 2011), self-expanding THV compression is conceivable in the presence of significant frame fracture, and thus, a thorough evaluation of THV function is recommended following CPR irrespective of the prosthesis design.
Outside of the setting of CPR, THV frame fracture has not been reported. It has been suggested that relocating the site of chest compressions toward the left hemithorax could provide adequate haemodynamic support and avoid potential THV compression. 88 Treatment options for patients with THV deformation depend on the clinical scenario, and haemodynamic consequences of THV compression, but could include balloon post-dilatation, valve-in-valve implantation, or THV retrieval and SAVR.
Transcatheter heart valve thrombosis
Ten publications, comprising 15 individual cases of THV thrombosis, were identified ( Table 5) . 96 -105 The majority of cases (14 of 15) involved the Edwards SAPIEN THV. Excluding two cases of periprocedural thrombosis, the mean time to diagnosis was 9 + 7 months (range: 1-24 months). The post-implantation antiplatelet regimen was described in 13 cases: 12 patients were prescribed dual antiplatelet therapy (DAPT) consisting of aspirin and clopidogrel; one case was treated with aspirin monotherapy. One patient on aspirin alone and one non-compliant patient had THV thrombosis at 2 weeks and 8 months, respectively. The remaining patients had THV thrombosis after completing the recommended course of DAPT (on-going aspirin) (n ¼ 5) or despite on-going DAPT (n ¼ 6). Most patients with THV thrombosis presented with progressive dyspnoea (n ¼ 12). One patient was asymptomatic and the thrombosis was evident on post-implantation CT, one had a non-STsegment myocardial infarction, and one patient with peri-procedural THV thrombosis suffered cardiac arrest. The most commonly observed echocardiographic features were increasing transvalvular gradients (n ¼ 12), thickened THV leaflets with impaired mobility (n ¼ 8), and visualization of thrombus formation on the valve (n ¼ 5).
Transcatheter heart valve thrombosis was treated with either systemic anticoagulation (n ¼ 11) or surgical intervention (n ¼ 3). Thrombolytic therapy was not performed in any case. In all patients treated with anticoagulation, the transvalvular gradients diminished towards the post-procedural gradient and leaflet mobility normalized. Favourable clinical outcomes were noted for all patients, except the case of peri-procedural THV thrombosis complicated by cardiac arrest, progressive cardiogenic shock and death. Protracted hospital stay was described for two of the three patients who underwent surgical thrombectomy and SAVR.
Discussion: Transcatheter heart valve thrombosis
Thrombosis of surgical aortic bioprostheses is rare, with incidence estimates of 0.03-0.7% per patient-year.
106, 107 Transcatheter heart valve thrombosis appears to be an equally rare event: there were no reported cases of prosthesis thrombosis in the PARTNER randomized trials or in large consecutive TAVI registries. 4, 5, 16 One case of THV thrombosis (0.8%) was reported among the 130 TAVI recipients enrolled in the PARTNER EU trial. Other abbreviations as in Table 1 . CPB, cardiopulmonary bypass.
There exist, however, several theoretical mechanisms that could potentially increase the risk of THV thrombosis relative to SAVR ( Figure 7) : 108 (i) the elderly TAVI population is more likely to have coexisting prothrombotic conditions (e.g. Cancer), (ii) the metallic THV frame could potentially provide a nidüs for thrombosis, (iii) incomplete THV expansion can create leaflet folds and potential recesses for thrombus formation, (iv) incomplete THV apposition to the aortic wall may delay endothelialization, and (v) the native leaflets may overhang balloon-expandable systems creating areas of diminished blood flow and stagnation. It appears that the highest risk of valve thrombosis following bioprosthetic SAVR occurs in the first 3-6 months post-operatively. 109 Consequently, aspirin therapy (75-100 mg) is recommended by societal guidelines. 110, 111 More recently, short-term use of oral anticoagulation has been associated with a reduction in thromboembolic events and cardiovascular mortality. 109 There are currently few data evaluating the efficacy of either antiplatelet or anticoagulant therapy following TAVI. 112 Dual antiplatelet therapy (aspirin and clopidogrel) is presently recommended for 3-6 months post-TAVI, though there is scant evidence to support the selection or duration of this regimen. This rather arbitrary duration of therapy aims to provide antiplatelet cover in the immediate post-operative period, allowing THV frame endothelialization, without exposing the patient to excessive bleeding risk. It is unclear if a short period of oral anticoagulation could reduce the risk of both stroke and potential for THV thrombosis without prohibitively increasing the bleeding risk. On-going research will help define the optimal duration of antiplatelet therapy post-TAVI (Aspirin Versus Aspirin and ClopidogRel 
Continued
Transcatheter heart valve failure Following Transcatheter Aortic Valve Implantation: the ARTE Trial: NCT01559298) and/or need for anticoagulation.
It should be noted that the diagnosis of THV thrombosis requires a high index of suspicion: thrombus was not seen on either the THV leaflets or frame in two-thirds of cases. Diagnostic clues include a history of non-compliance with DAPT, 96 echocardiographic evidence of progressive valve dysfunction (usually stenosis), 96, 99, 102 leaflet thickening, and immobility. 101 -103 The optimal management of THV thrombosis is currently unclear. It is noteworthy that three-quarters of cases were successfully treated with prolonged systemic anticoagulation and that thrombolysis was not performed in any case, probably due to the high risk of bleeding in TAVI patients. Surgical thrombectomy and SAVR was successful performed in three cases, without procedural mortality.
Discussion
The main findings of this systematic review of published data on TAVI failure are that THVs appear to be susceptible to failure modes both similar to those of surgical bioprosthetic valves and unique to the specific design features of THVs. Late embolization and THV compression represent complications previously unreported in the surgical literature.
Surgical aortic valve replacement failure
Surgical bioprosthetic failure may be attributed to SVF, IE, thrombosis, or paravalvular leak. First generation bioprosthetic valves were particularly prone to SVF, with up to one-third of younger patients requiring reoperation within 10 years of implantation. 113 Advances in prosthesis design, leaflet fixation, and anti-calcification treatment have rendered these early prostheses obsolete, and have improved valve durability: freedom from SVF at 15 years was reported in 43% of those treated with the first generation Hancock (Medtronic, Minneapolis, MN, USA) and in 19% treated with the second-generation Hancock. 114, 115 Current, third-generation bioprostheses are expected to further reduce the incidence of SVF and long-term follow-up data on these prostheses are eagerly awaited.
Transcatheter heart valve failure
We observed three THV failure modes (PVE, SVF, and thrombosis) that are synonymous with surgical bioprosthesis failure. We observed some variance, however, in the presentation and management of these complications between TAVI and SAVR. For example, confirming the diagnosis of PVE appeared to be more difficult among TAVI recipients than expected; echocardiographic diagnosis appeared to be hindered by limited visualization of the THV and by the frequent presence of post-implantation paravalvular leaks. Structural valve failure was also more frequently treated with redo TAVI rather than SAVR. Two failure modes, unique to THVs were also identified. Late THV embolization is a rare, but potentially catastrophic complication of TAVI. The limited number of events precludes an analysis of potential risk factors for late embolization, though insufficient THV anchoring, low implantation, and the presence of a mitral prosthesis were prevalent amongst cases. Compression of balloon-expandable THV was reported among patients that had undergone CPR in the setting of fatal peri-procedural complications. Thus, THV function should be evaluated following CPR in all THV recipients.
Implications
Understanding the modes of TAVI failure, their presentation, treatment, and outcomes is of particular relevance as TAVI technology is applied to greater patient numbers worldwide and increasingly to intermediate-risk cohorts. 1,2 The current study highlights several modes of TAVI failure that will be seen with greater frequency as experience with the technique increases. It is likely that the current case report and small series literature on TAVI failure reflects a significant underreporting of events. Therefore, determining the true incidence of adverse events will require high-quality dedicated post-marketing surveillance registries, such as the Society of Thoracic Surgeons/ American College of Cardiology Transcatheter Valve Therapy registry. 116 The objective performance criteria developed by the U.S.
Food and Drug Administration will provide benchmark performance for evaluating the long-term performance of TAVI technology. 117 Systematic autopsy of TAVI recipients could also facilitate our understanding of the modes of TAVI failure as distinct from bioprosthetic SAVR failure.
Limitations
This study has the limitations inherent to all systematic reviews. We present only the information described in each individual publication and therefore potentially omit relevant data. All the articles in the literature were either case reports or small series, precluding comparison with the entire TAVI population at risk. Furthermore, accurate estimation of the true incident rates of each THV failure mode was not possible, and the likely underreporting of adverse events would be expected to result in a significant underestimation of event rates. In addition, the management of patients in published case reports and small series may not represent common clinical practice but nonetheless provide some clinical guidance in circumstances where an evidence base is not available. The results of this review are also subject to publication bias as the reported incidences and individual patient outcomes may have been superior to those that were not published. Furthermore, imaging data and other relevant background information were not available in all the reported cases.
Conclusions
Transcatheter heart valves appear to be susceptible to failure modes both similar to those of surgical bioprosthetic valves and unique to the specific design features of THVs. Late embolization and THV compression represent complications previously unreported in the surgical literature. Large patient series with extended follow-up are required to better characterize and quantify THV failure.
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